On March 31st 2022, RemeGen(Name: 荣昌生物, Code: 688331) announced its successful listing on SSE STAR Market, officially start its "A+H" dual-channel era.rythematosus and lupus nephritis deserves further in-depth study.
RemeGen was founded in 2008, headquartered in Yantai, Shandong Province of China, with research labs and offices throughout Beijing, Shanghai, San Francisco and Washington. RemeGen is committed to the discovery, development and commercialization of innovative first-in-class and best-in-class biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology and ophthalmic diseases.
Presently, we have discovered and developed more than 20 biologic candidates. Seven products have entered clinical trials for more than 20 indications. Telitacicept(RC18) and Disitamab Vedotin(RC48) had been granted approval by NMPA in March and June 2021 and were also included in the National Reimbursement Drug List (NRDL) in the same year.
On November 9th, 2020, RemeGen(荣昌生物-B，09995.HK) successful listed on the HKEX, attracted nineteen world's top investment institutions like Fidelity International, BlackRock, OrbiMed, Hillhouse Capital Group, and Lilly Asia Ventures as cornerstone investors, raised $590 million, and created the world's largest biotechnology IPO record in 2020.
